{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:38:25Z","timestamp":1717425505501},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.patbio.2012.05.010","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T05:23:06Z","timestamp":1340774586000},"page":"239-245","source":"Crossref","is-referenced-by-count":7,"title":["Leuc\u00e9mie my\u00e9lo\u00efde chronique\u00a0: \u00ab\u00a0arch\u00e9type\u00a0\u00bb de l\u2019impact des traitements cibl\u00e9s"],"prefix":"10.1016","volume":"60","author":[{"given":"R.","family":"Nasr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.patbio.2012.05.010_bib0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis","volume":"1","author":"Radich","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.patbio.2012.05.010_bib0015","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood","volume":"J64","author":"Bennett","year":"1845","journal-title":"Edinb Med Surg"},{"key":"10.1016\/j.patbio.2012.05.010_bib0020","first-page":"151","article-title":"Weisses blut","volume":"36","author":"Virchow","year":"1845","journal-title":"Frorieps Notizen"},{"key":"10.1016\/j.patbio.2012.05.010_bib0025","unstructured":"Neumann E. Ein Fall Von Leuk\u00e4mie Mit Erkrankung Des Knochenmarks. Archive der Heilkunde 1870."},{"key":"10.1016\/j.patbio.2012.05.010_bib0030","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"32","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.patbio.2012.05.010_bib0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.patbio.2012.05.010_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.patbio.2012.05.010_bib0050","first-page":"2213","article-title":"Lymphosarcoma: virus-induced thymic-independent disease in mice","volume":"30","author":"Abelson","year":"1970","journal-title":"Cancer Res"},{"key":"10.1016\/j.patbio.2012.05.010_bib0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.patbio.2012.05.010_bib0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.patbio.2012.05.010_bib0065","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia--advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0070","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.patbio.2012.05.010_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.patbio.2012.05.010_bib0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10428199309047857","article-title":"Ph-positive leukemia: a transgenic mouse model","volume":"11","author":"Groffen","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.patbio.2012.05.010_bib0085","series-title":"Leukemia and allied disorders","author":"Forkner","year":"1938"},{"key":"10.1016\/j.patbio.2012.05.010_bib0090","first-page":"3409","article-title":"BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity","volume":"60","author":"Puccetti","year":"2000","journal-title":"Cancer Res"},{"issue":"7198","key":"10.1016\/j.patbio.2012.05.010_bib0095","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.patbio.2012.05.010_bib0100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0140-6736(53)90885-X","article-title":"Myleran in chronic myeloid leukaemia; results of treatment","volume":"264","author":"Galton","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2012.05.010_bib0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00062752-199704060-00002","article-title":"Allografting for chronic myeloid leukemia","volume":"4","author":"Savage","year":"1997","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.patbio.2012.05.010_bib0110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0115","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","article-title":"Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients","volume":"114","author":"Talpaz","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0120","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2012.05.010_bib0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0130","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.patbio.2012.05.010_bib0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1986.tb07576.x","article-title":"Chronic myelogenous leukaemia: haematological remissions with alpha interferon","volume":"64","author":"Talpaz","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.patbio.2012.05.010_bib0140","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood.V82.12.3524.3524","article-title":"Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562\u00a0to differentiate","volume":"82","author":"Anafi","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2012.05.010_bib0145","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0150","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2012.05.010_bib0155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis","volume":"23","author":"Gambacorti-Passerini","year":"1997","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.patbio.2012.05.010_bib0160","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0170","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.patbio.2012.05.010_bib0175","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.patbio.2012.05.010_bib0180","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.patbio.2012.05.010_bib0185","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0350","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/asheducation-2008.1.419","article-title":"Milestones and monitoring in patients with CML treated with imatinib","volume":"1","author":"Deininger","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.patbio.2012.05.010_bib0195","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.patbio.2012.05.010_bib0200","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2\u00a0study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.patbio.2012.05.010_bib0205","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.patbio.2012.05.010_bib0210","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.patbio.2012.05.010_bib0215","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","article-title":"Therapy options in imatinib failures","volume":"13","author":"Ramirez","year":"2008","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.patbio.2012.05.010_bib0220","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.patbio.2012.05.010_bib0225","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.patbio.2012.05.010_bib0230","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.patbio.2012.05.010_bib0235","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/ehm.09.42","article-title":"Bosutinib: a dual SRC\/ABL kinase inhibitor for the treatment of chronic myeloid leukemia","volume":"2","author":"Keller","year":"2009","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.patbio.2012.05.010_bib0240","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.patbio.2012.05.010_bib0245","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"issue":"35","key":"10.1016\/j.patbio.2012.05.010_bib0250","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.patbio.2012.05.010_bib0255","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.patbio.2012.05.010_bib0260","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.patbio.2012.05.010_bib0265","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1\u00a0gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.patbio.2012.05.010_bib0270","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.patbio.2012.05.010_bib0275","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400\u00a0to 600milligrams daily: two-year follow-up of a randomized phase 2\u00a0study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"issue":"5538","key":"10.1016\/j.patbio.2012.05.010_bib0280","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI-571\u00a0cancer therapy","volume":"293","author":"Barthe","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.patbio.2012.05.010_bib0285","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.patbio.2012.05.010_bib0290","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.patbio.2012.05.010_bib0355","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.patbio.2012.05.010_bib0300","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.seminhematol.2010.06.004","article-title":"Third-generation tyrosine kinase inhibitors and beyond","volume":"47","author":"Quintas-Cardama","year":"2010","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1016\/j.patbio.2012.05.010_bib0305","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2012.05.010_bib0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2011.09.025","article-title":"Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model","volume":"36","author":"Schultheis","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.patbio.2012.05.010_bib0315","doi-asserted-by":"crossref","unstructured":"Leguay T, Mahon FX. Leuc\u00e9mie my\u00e9lo\u00efde chronique. H\u00e9matologie 2005;13-011-B-10.","DOI":"10.1016\/S1155-1984(05)39940-7"},{"issue":"6","key":"10.1016\/j.patbio.2012.05.010_bib0320","first-page":"653","article-title":"Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?","volume":"21","author":"Jabbour","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"8\u00a0Suppl.\u00a0A","key":"10.1016\/j.patbio.2012.05.010_bib0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.18553\/jmcp.2007.13.s8-a.13","article-title":"New strategies in controlling drug resistance","volume":"13","author":"Frame","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.patbio.2012.05.010_bib0330","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0335","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2012.05.010_bib0340","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571\u00a0in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2012.05.010_bib0345","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study","volume":"358","author":"Van Oosterom","year":"2001","journal-title":"Lancet"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811412000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811412000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T15:12:25Z","timestamp":1642605145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811412000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0369811412000910"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2012.05.010","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}